Synergy of bovine lactoferrin with the anti-cytomegalovirus drug cidofovir in vitro (Q44438126)

3 December 2017

Synergy of bovine lactoferrin with the anti-cytomegalovirus drug cidofovir in vitro (English)

1 reference

3 December 2017

0 references

5

1 reference

3 December 2017

Barry W A van der Strate

1

1 reference

3 December 2017

Froukje M De Boer

2

1 reference

3 December 2017

Hester I Bakker

3

1 reference

3 December 2017

Dirk K F Meijer

4

1 reference

3 December 2017

Martin C Harmsen

6

1 reference

3 December 2017

1 April 2003

1 reference

3 December 2017

1 reference

3 December 2017

58

1 reference

3 December 2017

2

1 reference

3 December 2017

159-165

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

3 December 2017

1 reference

7 January 2021

Specific targeting of the antiviral drug 5-iodo 2'-deoxyuridine to the parenchymal liver cell using lactosylated poly-L-lysine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Human neutrophil granules and secretory vesicles.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

1 reference

7 January 2021

Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine and administered to mice by intramuscular route.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Ribavirin conjugated with lactosaminated poly-L-lysine: selective delivery to the liver and increased antiviral activity in mice with viral hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Hepatotropic conjugate of adenine arabinoside monophosphate with lactosaminated poly-L-lysine. Synthesis of the carrier and pharmacological properties of the conjugate

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Studies of viral co-factors for human immunodeficiency virus in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Effect of human milk prostaglandins and lactoferrin on respiratory syncytial virus and rotavirus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

A rapid assay for determination of antiviral activity against human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Anti-HIV-1 activity of combinations and covalent conjugates of negatively charged human serum albumins (NCAs) and AZT

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Antibiotic proteins of polymorphonuclear leukocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Lactoferrin: molecular structure and biological function

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

The causes of death in patients with human immunodeficiency virus infection: a clinical and pathologic study with emphasis on the role of pulmonary diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Neoglycoproteins as carriers for antiviral drugs: synthesis and analysis of protein-drug conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

A three-dimensional model to analyze drug-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Clinical uses of cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Cytomegalovirus ventriculoencephalitis in AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Protein-glycosaminoglycan interactions: infectiological aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Lactoferrin-mediated protection of the host from murine cytomegalovirus infection by a T-cell-dependent augmentation of natural killer cell activity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

The influence of cytomegalovirus on the natural history of HIV infection: evidence of rapid course of HIV infection in HIV-positive patients infected with cytomegalovirus.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Insertion and deletion mutagenesis of the human cytomegalovirus genome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Plasma lactoferrin levels are decreased in end-stage AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Antiviral activities of lactoferrin

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

Acyclovir: A Decade Later

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900211-5

7 January 2021

10.1016/S0166-3542(02)00211-5

Identifiers

DOI

1 reference

3 December 2017

1 reference